Stockscreener 앱 받기
4.75
1.28%
0.06
시장 영업 전:
4.71
-0.04
-0.84%
전일 마감가:
$4.69
열려 있는:
$4.65
하루 거래량:
11.83M
Relative Volume:
6.59
시가총액:
$913.54M
수익:
$12.99M
순이익/손실:
$-74.39M
주가수익비율:
-10.80
EPS:
-0.44
순현금흐름:
$-78.92M
1주 성능:
+3.26%
1개월 성능:
+22.42%
6개월 성능:
+18.45%
1년 성능:
+40.12%
1일 변동 폭
$4.30
$4.81
1주일 범위
$4.30
$4.81
52주 변동 폭
$2.705
$5.10
Arbutus Biopharma Corp Stock (ABUS) Company Profile
명칭
Arbutus Biopharma Corp
전화
604-419-3200
주소
701 VETERANS CIRCLE, WARMINSTER, PA
Compare ABUS vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ABUS
Arbutus Biopharma Corp
|
4.75 | 902.00M | 12.99M | -74.39M | -78.92M | -0.44 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.89 | 120.48B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
787.50 | 81.05B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
749.56 | 46.33B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.30 | 42.26B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
299.02 | 32.87B | 5.36B | 287.73M | 924.18M | 2.5229 |
Arbutus Biopharma Corp Stock (ABUS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2022-02-02 | 업그레이드 | Jefferies | Hold → Buy |
| 2021-02-25 | 개시 | Jefferies | Hold |
| 2020-12-17 | 개시 | H.C. Wainwright | Buy |
| 2020-07-27 | 재개 | JMP Securities | Mkt Outperform |
| 2020-07-24 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2020-05-19 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2020-03-06 | 업그레이드 | Chardan Capital Markets | Neutral → Buy |
| 2020-02-20 | 개시 | Robert W. Baird | Outperform |
| 2020-02-05 | 업그레이드 | JMP Securities | Mkt Perform → Mkt Outperform |
| 2019-10-07 | 재확인 | B. Riley FBR | Buy |
| 2019-10-04 | 다운그레이드 | Chardan Capital Markets | Buy → Neutral |
| 2018-10-16 | 업그레이드 | B. Riley FBR | Neutral → Buy |
| 2018-10-15 | 업그레이드 | Wedbush | Underperform → Neutral |
| 2018-10-12 | 재확인 | Chardan Capital Markets | Buy |
| 2018-07-06 | 다운그레이드 | B. Riley FBR, Inc. | Buy → Neutral |
| 2018-03-19 | 재개 | Chardan Capital Markets | Buy |
| 2018-03-19 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2018-01-05 | 개시 | B. Riley FBR, Inc. | Buy |
| 2017-04-04 | 업그레이드 | Chardan Capital Markets | Neutral → Buy |
| 2017-02-01 | 재확인 | Wedbush | Outperform |
| 2016-12-13 | 다운그레이드 | Chardan Capital Markets | Buy → Neutral |
| 2016-11-30 | 업그레이드 | Chardan Capital Markets | Neutral → Buy |
모두보기
Arbutus Biopharma Corp 주식(ABUS)의 최신 뉴스
Moderna reaches $950 million settlement with Arbutus and Genevant over patent litigation - Investing.com
Here's Arbutus Biopharma's share of $950M Moderna settlement - The Business Journals
Arbutus Biopharma (NASDAQ:ABUS) Sees Strong Trading VolumeWhat's Next? - MarketBeat
Arbutus Biopharma (ABUS) Reaches Settlement with Moderna Over Pa - GuruFocus
Chardan reiterates Arbutus Biopharma stock rating on Moderna deal By Investing.com - Investing.com Canada
MRNA Stock Gains on $2.25B Deal to Settle Patent Dispute With ROIV, ABUS - Finviz
Chardan reiterates Arbutus Biopharma stock rating on Moderna deal - Investing.com
ABUS: Key Developments and Market Impact - GuruFocus
Moderna's $950 Million Settlement Clears Legal Overhang, Stock Soars - Benzinga
Moderna to pay about US$1 bil to settle Arbutus litigation - The Edge Malaysia
Genevant and Arbutus agree $2.25 billion global settlement with Moderna - The Pharma Letter
Moderna to Pay About $1 Billion to Settle Arbutus Litigation - Bloomberg.com
Why Box Shares Are Trading Higher By Over 6%; Here Are 20 Stocks Moving Premarket - Benzinga
Moderna Shares Rise 16% After Company Enters Settlement Agreement With Arbutus Biopharma, Genevant Sciences - Bitget
Moderna to pay Genevant Sciences and Arbutus Biopharma up to $2.25 billion in global patent settlement - PharmaLive
Arbutus Biopharma (ABUS) and Genevant Reach $2.25 Billion Settle - GuruFocus
Arbutus Biopharma Reaches Transformative Global Settlement With Moderna - TipRanks
Roivant, Arbutus Biopharma stocks surges on $2.25B Moderna settlement - Investing.com
Roivant's Genevant and Arbutus reach $2.25 billion settlement with Moderna - StreetInsider
Arbutus Biopharma (Nasdaq: ABUS) details $2.25B Moderna patent settlement - Stock Titan
Genevant Sciences and Arbutus Biopharma Announce $2.25 Billion Global Settlement With Moderna - GlobeNewswire
Moderna Royalty Loss Raises Covid-Shot Trial Stakes (Correct) - Bloomberg Law News
Arbutus Biopharma wins partial summary judgment on Moderna defenses; enablement dispute to go to jury - TradingView
Key patent ruling boosts Arbutus Biopharma (NASDAQ: ABUS) in Moderna LNP case - Stock Titan
Genevant Sciences and Arbutus Biopharma Initiate International Patent Infringement Enforcement Actions Against Moderna - Intellectia AI
Delaware Court Narrows Moderna’s Invalidity Defenses Ahead of Arbutus LNP Patent Trial - IPWatchdog.com
Arbutus Biopharma (NASDAQ:ABUS) Stock Price Crosses Above 200-Day Moving AverageHere's What Happened - MarketBeat
Two Seas Capital reports 6.5% Arbutus Biopharma (ABUS) ownership - Stock Titan
What insider trading reveals about Arbutus Biopharma Corporation stockMarket Risk Summary & Fast Entry and Exit Trade Plans - mfd.ru
Will Arbutus Biopharma Corporation stock remain a Wall Street favorite2025 Top Decliners & Comprehensive Market Scan Insights - mfd.ru
Moving Averages: How does Arbutus Biopharma Corporation correlate with NasdaqWeekly Investment Report & Smart Investment Allocation Insights - baoquankhu1.vn
Court narrows but sustains Arbutus (NASDAQ: ABUS) patent claims in Moderna COVID-19 vaccine fight - Stock Titan
PATENT—D. Del.: Most COVID-19... - VitalLaw.com
Moderna Again Fails to Shift Most Covid-Shot Patent Costs to US - Bloomberg Law News
Arbutus Biopharma (NASDAQ:ABUS) Stock Price Down 6.8%What's Next? - MarketBeat
Patent Ruling Update Affects Arbutus Biopharma (ABUS) in Legal B - GuruFocus
Arbutus Biopharma (ABUS) Rises on Patent Dispute Jury Trial Deci - GuruFocus
Arbutus Biopharma (ABUS) Shares Surge Amid Market Fluctuations - GuruFocus
Arbutus Biopharma (ABUS) Patent Dispute Over COVID-19 Vaccine De - GuruFocus
Arbutus jumps on ruling in patent dispute with Moderna (ABUS:NASDAQ) - Seeking Alpha
Traders Buy Large Volume of Call Options on Arbutus Biopharma (NASDAQ:ABUS) - MarketBeat
Aug Drivers: Can Arbutus Biopharma Corporation ride the EV waveQuarterly Investment Review & Consistent Return Strategy Ideas - baoquankhu1.vn
Arbutus Biopharma (NASDAQ:ABUS) Stock Passes Above 200-Day Moving AverageHere's What Happened - MarketBeat
Aug Closing: Should I buy Arbutus Biopharma Corporation stock nowJuly 2025 Volume & Weekly High Momentum Picks - baoquankhu1.vn
Arbutus Biopharma (ABUS) Patent Invalidated by European Patent O - GuruFocus
Arbutus Biopharma (ABUS) Faces Patent Revocation in Europe - GuruFocus
ABUS Stock Tumbles on European Patent Revocation - StocksToTrade
Arbutus Biopharma (ABUS) Shares Drop Amid Patent Revocation - GuruFocus
Market Dynamics Cause Shifts for Arbutus Biopharma - StocksToTrade
Arbutus Biopharma (ABUS) Patent Revocation Leads to 18% Stock Crash - Intellectia AI
Arbutus Biopharma (NASDAQ:ABUS) Shares Gap DownHere's Why - MarketBeat
Arbutus Biopharma Corp (ABUS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.11%
6.00%
자본화:
|
볼륨(24시간):